Pfizer May Challenge GLP-1 Weight Loss Duopoly

Pfizer is reportedly developing a monthly weight loss injection that could potentially disrupt the current duopoly held by Eli Lilly and Novo Nordisk in the GLP-1 drug market. While Lilly and Novo Nordisk dominate the obesity treatment landscape, Pfizer's potential offering might present a uniquely marketable alternative. The development signifies a competitive push in the lucrative weight-loss drug sector, with pharmaceutical giants vying for a significant share of this rapidly expanding market.